TScan Therapeutics, Inc. — Form D
TScan Therapeutics, Inc. of Waltham, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-01-28. The offering totals $100.0M, of which $100.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-01-28
- Form: D
- Accession: 0001783328-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $100.0M
- Amount sold: $100.0M
- Investors: 16
- Date of first sale: 2021-01-15
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-387638
Issuer
- Name: TScan Therapeutics, Inc.
- CIK: 0001783328
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 830 Winter Street, Waltham, MA, 02451
- Phone: 857-399-9500
Officers, directors & promoters (14)
| Name | Role | Location |
|---|
| Timothy Barberich | Director | Edina, MN |
| Doug Fambrough | Director | Waltham, MA |
| Ittai Harel | Director | College Park, GA |
| Andrew Hedin | Director | Claymont, DE |
| Nandita Shangari | Director | Boston, MA |
| Brian Silver | Director | Waltham, MA |
| David Southwell | Director | NEW YORK, NY |
| Christoph Westphal | Director | CAMBRIDGE, MA |
| David Southwell | Executive Officer | NEW YORK, NY |
| Steve Kraus | Director | Timonium, MD |
| Robert Crane | Executive Officer | Cambridge, MA |
| Lea Hachigian | Director | Boston, MA |
| Campbell Murray | Director | NOVATO, CA |
| Hannes Smarason | Director | Boston, MA |
Other filings by this issuer (1)
More